Vertex Pharmaceuticals Simultaneous Announcements Vertex Pharmaceuticals (VRTX) announced simultaneous presentation and publication of updated data from Phase 1/2 portion of Phase 1/2/3 FORWARD-101 clinical trial in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in oral presentation at the American Diabetes Association (ADA . . . This content is for paid subscribers. Please click here to subscribe …

Cidara Therapeutics Cidara Therapeutics uses its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track …

Exelixis in the NEWS Exelixis (EXEL) announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Akero Therapeutics Akero Therapeutics (AKRO) - a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Currently, many investors, including us, believe that . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Exelixis in the NEWS   Two days ago, Exelixis (EXEL) reported financial results for the first quarter of 2025, providing an update on the firm’s progress toward achieving key corporate objectives, and outlined its commercial, clinical, and pipeline development milestones. From Exelixis Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis said, " Exelixis has delivered outstanding financial performance . . . This content is …

Yesterday's Market and CytomX Therapeutics May 12, 2025 was an excellent day for many stressed countries. The good day began following the U.S. and China’s announcement of an agreement on Tariffs Many countries have been stressed since being attacked by COVID-19 and then the war in Europe and the Middle East as well as unparallelled inflations.   Yesterday, the Stock market rallied and with it …

PTC Therapeutics On May 6, 2025, PTC Therapeutics (PTCT) announced a corporate update and financial results for the first quarter ended March 31, 2025. We loved the firm’s strong revenue performance of $190 million,  the positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, and, important is the  NDA review remained on track for July 29, 2025, PDUFA date, the . . . This …

Important News from AbbVie AbbVie (ABBV) submitted a biological license application (BLA) to the United States’ FDA for its sensational product trenibotulinumtoxinE (TrenibotE), which reduces frown lines between the eyebrows, known as glabellar lines. The Product TrenibotE is a botulinum toxin of serotype E with short effects of a long duration for the users. The product is safer than the existing . . . This …

We still believe in many outperforming biotechnology firms whose stocks are underestimated on Wall Street. We believe these firms are outperforming in science but not yet in the Stock Market. We will continue to post them on our website. One of the firms that we recently liked after assessment is Vera Therapeutics.   Vera Therapeutics Vera Therapeutics (

Halozyme Therapeutics Q & A Yesterday, Halozyme Therapeutics (HALO) announced that Argenx Company (ARGX) has received . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Today's Stock Market Rally Today, Wednesday, April 9, 2025 the news started with Trump announcing a '90-day pause' on tariffs for most countries. What happened next was a rallying Stock Market with the Dow, the S&P 500 and the Nasdaq soaring.   The S&P 500 climbed up around 8%, the Nasdaq Composite rallied 10% and the Dow Jones Industrial Average was up over 7%. President …

Rhythm Pharmaceuticals Rally Last week, almost all the stocks tumbled. On Monday, the first day of the current week, we could see biotech firms usually moving up after good news, which didn’t occur during the few bad days of the market's tumbling.  One of the health firm’s sectors Rhythm Pharmaceuticals (RYTM) rallied after having more promising news . . . This content is for paid subscribers. …

Novo Nordisk in the NEWS Novo Nordisk (NVO) presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) in adults with type 2 diabetes and PAD, at the American College of Cardiology's (ACC) Annual Scientific Session and Expo in Chicago, US . . . This content is for paid subscribers. …

Stock Market Plummet and Alnylam Pharmaceuticals Good News Today, the stock market is plummeting. In fact, most stocks have been falling since early morning. The reason has nothing to do with the company’s activities. The best companies with the best science and scientists are sinking into the bottom of the deepest ocean today. Even though the Stock Market is surrounded by negativity, we will still …

Wave Life Sciences On March 26, 2025, Wave Life Sciences (WVE) announced positive data from the Phase 2 FORWARD-53 trial of WVE-N531, an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. FORWARD-53 Trial demonstrates sustained and industry-leading exon . . . This content is for paid subscribers. Please click here to subscribe or here to log …

PTC Therapeutics Inc On March 20, 2025, PTC Therapeutics, Inc. (PTCT) shared new data from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. These data provide further evidence of the potential meaningful benefits of sepiapterin treatment for the full spectrum of phenylketonuria (PKU . . . This content is for paid …

AstraZeneca and Daiichi Sankyo AstraZeneca (AZN) and Daiichi Sankyo’s (DSKYF) (trastuzumab deruxtecan) has been recommended for approval in . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Sanofi New Data Paris, February 28, 2025, Sanofi (SNY) will present 26 abstracts, including one late-breaking presentation and five additional oral presentations, on approved and investigational medicines at the American Academy of Dermatology (AAD) Annual Meeting in Orlando, FL, US, from March 7 to 11 . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Verona Pharma Conference Announcements Verona Pharma (VRNA) announces that senior management will present a company overview at the following conferences in March 2025: TD Cowen 45th Annual Health Care Conference Date: Monday, March 3, 2025: Time: 11:10 a.m. ET / 4:10 p.m. GMT Location: Boston, MA Leerink Partners 2025 Global Healthcare . . . This content is for paid subscribers. Please click here to subscribe or …

Gilead Sciences On February 20, 2025, Gilead Sciences (GILD) announced that the European Commission (EC) granted conditional marketing authorization to seladelpar in combination with ursodeoxycholic acid (UDCA) for the treatment of Primary Biliary Cholangitis (PBC) in adults who have inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Now approved, Seladelpar (an orphan-designated . . . This content is for …